4SC

4SC

4SC develops orally available small molecule drugs for the treatment of cancer and autoimmune diseases focusing on epigenetic targets.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Actelion

Actelion

Actelion went public on the Swiss Stock Exchange in 2000. It had a market cap of around CHF17B before its acquisition in 2017 by J&J for US$30B.

Location: Switzerland

Wellington contact: Rainer Strohmenger

Go to website
Adrenomed

Adrenomed

Adrenomed develops a first-in-class monoclonal antibody (Adrecizumab) that targets the vasoactive Adrenomedullin system as a new strategy for causative and safe treatment of acute circulatory failure, e.g. septic shock.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
AMBOSS

AMBOSS

AMBOSS’ mission is to make medical knowledge universally accessible and effective for medical students and professionals.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Atopix

Atopix

Atopix was acquired by Chiesi Farmaceutici in 2016 for more than €75M.

Location: United Kingdom

Wellington contact: Regina Hodits

Go to website
AyoxxA

AyoxxA

Ayoxxa markets its innovative, patented beads-on-a-chip technology (LUNARIS™) to analyze multiple biomarkers in very low volume biological samples.

Location: Germany

Wellington contact: Regina Hodits

Go to website
Carisma Therapeutics

Carisma Therapeutics

Carisma Therapeutics is pioneering the development of novel immunotherapies based on CAR macrophages.

Location: USA

Wellington contact: Regina Hodits

Go to website
confo therapeutics

confo therapeutics

Confo utilizes pioneering G protein-coupled receptor (GPCR) technology to build up a portfolio of first-in-class programs addressing difficult-to-drug disease targets in high need indications in neurology and beyond.

Location: Belgium

Wellington contact: Marianne Mertens, Regina Hodits

Go to website
Creative Balloons

Creative Balloons

Creative Balloons develops and markets novel catheter technology based on microscopically thin, complex shaped balloon films made of polyurethane (PUR).

Location: Germany

Wellington contact: Karl Nägler

Go to website
Definiens

Definiens

Definiens was acquired by MedImmune in 2015 for US$150M plus earnouts.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
eGenesis

eGenesis

eGenesis is a gene editing and genome engineering company committed to the development of safe and effective human transplantable organs, tissues and cells to address the global organ crisis.

Location: USA

Wellington contact: Rainer Strohmenger

Go to website
Evolva

Evolva

Evolva (SWX: EVE) is focused on discovering, producing and supplying innovative, sustainable ingredients for health, wellness and nutrition.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website
Genkyotex

Genkyotex

Genkyotex (EPA: GKTX) is developing first-in-class selective inhibitors of NOX enzymes for an orphan fibrotic disease as well as for angiogenesis, pain and inflammation.

Location: France

Wellington contact: Rainer Strohmenger

Go to website
Grandis Biotech

Grandis Biotech

Grandis was acquired in 2000 by Novartis.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
ImCheck Therapeutics

ImCheck Therapeutics

ImCheck Therapeutics develops antibody-based therapeutics targeting a novel class of immunomodulators (butyrophilins), with primary focus on activating a yet unexploited population of immune cells (γδ T-cells) for the treatment of cancer.

Location: France

Wellington contact: Karl Nägler

Go to website
Imevax

Imevax

ImevaX develops a novel therapeutic vaccine for treatment of Helicobacter pylori, the cause of gastric cancer, by targeting essential bacterial immune evasion factors.

Location: Germany

Wellington contact: Erich Schlick

Go to website
Immatics

Immatics

Immatics is developing Adoptive Cell Therapy (ACT) and soluble T cell receptor (sTCR) approaches based on the company's unrivalled XPRESIDENT cancer target discovery platform.

Location: Germany

Wellington contact: Erich Schlick

Go to website
Implanet Partners

Implanet Partners

Implanet specializes in development and commercialization of proprietary orthopedic implants with a focus on spine (JAZZ platform) and knee.

Location: France

Wellington contact: Rainer Strohmenger

Go to website
invendo

invendo

invendo was acquired in 2017 by Ambu A/S for up to €225M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
iOmx

iOmx

iOmx is a next-generation immuno-oncology company focused on novel pathways for T cell evasion by cancer.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Koa Health

Koa Health

Koa Health is a digital mental healthcare provider redefining care by offering a range of personalised mental health solutions backed by science and designed to improve user wellbeing.

Location: Netherlands

Wellington contact: Rainer Stohmenger

Go to website
Middle Peak Medical

Middle Peak Medical

Middle Peak Medical was acquired by Symetis in 2017.

Location: Germany

Wellington contact: Regina Hodits

Go to website
MinervaX

MinervaX

MinervaX is developing a novel protein-based maternal vaccination to protect newborns from life-threatening Group-B Streptococcal infections.

Location: Denmark

Wellington contact: Karl Nägler

Go to website
mtm laboratories

mtm laboratories

mtm labs was acquired by Roche in 2011 for up to US$273M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
Neuway Pharma

Neuway Pharma

NEUWAY Pharma is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases based on its proprietary CNS drug delivery platform.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
NoemaLife

NoemaLife

NoemaLife went public on Borsa Italiana in 2006 and was acquired by Dedalus in 2016.

Location: Italy

Wellington contact: Rainer Strohmenger

Go to website
ONWARD

ONWARD

ONWARD is creating technologies to improve the movement, independence, and health of people with spinal cord injury.

Location: The Netherlands & Switzerland

Wellington contact: Regina Hodits

Go to website
Oxford Immunotec

Oxford Immunotec

Oxford Immunotec (NASDAQ: OXFD) focuses on developing and commercializing proprietary tests for latent tuberculosis and management of immune-regulated conditions.

Location: United Kingdom

Wellington contact: Rainer Strohmenger

Go to website
Polares Medical

Polares Medical

Polares Medical develops a novel mitral valve repair system which can be implanted minimally invasively. Polares Medical was created as a spin-off of Symetis.

Location: USA

Wellington contact: Regina Hodits

Go to website
Quanta Dialysis Technologies

Quanta Dialysis Technologies

Quanta is developing and marketing easy-to-use and portable haemodialysis systems with full clinical performance for use in the home and clinic.

Location: United Kingdom

Wellington contact: Rainer Strohmenger

Go to website
Rigontec

Rigontec

Rigontec was acquired by Merck & Co. in 2017 for up to US$553M.

Location: Germany

Wellington contact: Regina Hodits

Go to website
Sapiens Steering Brain Stimulation

Sapiens Steering Brain Stimulation

Sapiens was acquired by Medtronic in 2014 for US$200M.

Location: Netherlands

Wellington contact: Regina Hodits

Go to website
Sensimed

Sensimed

Sensimed has developed a digital contact lens with telemetry features - the Triggerfish® - that provides automated 24h recording of continuous ocular dimensional / intraocular pressure changes for Glaucoma management.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website
SidekickHealth

SidekickHealth

SidekickHealth develops gamified digital therapeutic solutions to supports people with chronic diseases. The company operates a patient centric digital care platform.

Location: Sweden / USA / Iceland

Wellington contact: Regina Hodits

Go to website
SIRS Therapeutics

SIRS Therapeutics

SIRS develops a fibrin-derived peptide (FX06) for the treatment of diseases related to vascular leakage e.g., ARDS in patients with underlying COVID-19 infection.

Location: Germany

Wellington contact: Karl Nägler

Go to website
SNIPR BIOME

SNIPR BIOME

SNIPR BIOME develops CRISPR-based drug candidates for difficult-to-treat infections and microbiome engineering in auto-immune and malignant disorders.

Location: Denmark

Wellington contact: Regina Hodits, Marianne Mertens

Go to website
Sphingotec

Sphingotec

sphingotec develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website
STipe Therapeutics

STipe Therapeutics

STipe Therapeutics is developing first-in-class drugs targeting intracellular protein-protein interactions of the STING pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders.

Location: Denmark

Wellington contact: Regina Hodits

Go to website
Supersonic Imagine

Supersonic Imagine

SuperSonic Imagine (EPA:SSI) markets a unique imaging system combining shear wave elastography with conventional ultrasound, a new method to visualize soft tissues and diffentiate malignant from normal tissues at early tumor stages.

Location: France

Wellington contact: Erich Schlick

Go to website
Symetis

Symetis

Symetis was acquired by Boston Scientific in 2017 for US$435M.

Location: Switzerland

Wellington contact: Erich Schlick

Go to website
Technolas Perfect Vision

Technolas Perfect Vision

Technolas Perfect Vision was acquired by Bausch & Lomb in 2013 for more than US$400M.

Location: Germany

Wellington contact: Rainer Stromenger

Go to website
Themis Bioscience

Themis Bioscience

Themis is developing vaccines to prevent infectious diseases based on its Themaxyn™ platform with an emphasis on emerging tropical diseases and large unmet need indications.

Location: Austria

Wellington contact: Regina Hodits

Go to website
TRiCares

TRiCares

TRiCares is developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.

Location: Germany/France

Wellington contact: Regina Hodits, Erich Schlick

Go to website
UroMems

UroMems

Uromems is developing an active implantable medical device for treating male and female stress urinary incontinence.

Location: France

Wellington contact: Rainer Strohmenger

Go to website
Wavelight

Wavelight

Wavelight went public on the Frankfurt Stock Exchange in 1999 and was acquired by Alcon in 2007 for more than US$90M.

Location: Germany

Wellington contact: Rainer Strohmenger

Go to website